22 Jan Obsidian Therapeutics
Madan Jagasia, M.D., CEO
April 10 | 4:30pm | Salone dei Cavalieri, Section 2
Cambridge, MA
(Private)
At Obsidian, we are pioneering engineered cell and gene therapies to deliver transformative outcomes for patients. OBX-115, our lead product candidate, is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy manufactured using a portion of the patient’s tumor tissue, from which TIL are isolated and engineered with a transgene to express membrane-bound human IL15 (mbIL15). The transgene construct encodes for a fusion protein that couples mbIL15 with a drug-responsive domain (DRD). The DRD is stabilized by administration of the small-molecule drug, acetazolamide (ACZ), which upon binding stabilizes the fusion protein, and allows for expression of mbIL15 on the cell surface of the TIL. mbIL15 drives the expansion and persistence of TIL, promoting elimination of tumor cells.
